Human chorionic gonadotropin as an angiogenic factor in breast cancer during pregnancy

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 1035-1040

  Michel, Rosa M ^a,b   Aguilar, José Luis ^a,b   Arrieta, Oscar ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; STEROID RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER INVASION; DISEASE ASSOCIATION; EPITHELIUM CELL; FEMALE; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; METASTASIS POTENTIAL; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS;

ADULT; ANGIOGENESIS INDUCING AGENTS; BREAST NEOPLASMS; CHORIONIC GONADOTROPIN; FEMALE; HUMANS; MODELS, BIOLOGICAL; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847056196     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.05.072     Document Type: Article

References (50)

1. Petrek J.A. Breast cancer and pregnancy. J Natl Cancer Inst Monogr 16 (1994) 113-121
2. Hoover H.C. Breast cancer during pregnancy and lactation. Surg Clin N Am 70 5 (1990) 1151-1163
3. Fedarapalli P., and Jain S. Breat cancer in pregnancy. J Obstet Gynaecol 26 1 (2006) 1-4
4. National Cancer Institute. Breast Cancer and pregnancy: ; February 24th 2006.
5. Psyrri A., and Burtness B. Pregnancy-associated breast cancer. Cancer J 11 2 (2005) 83-95
6. Petrek J.A., Dukoff J.R., and Rogatko A. Prognosis of pregnancy associated breast cancer. Cancer 67 4 (1991) 869-872
7. Gemignani M.L., and Petrek J.A. Pregnancy associated breast cancer: diagnosis and treatment. Breast J 6 1 (2000) 68-73
8. Horsley III J.S., Alrich E.M., and Wright C.B. Carcinoma of the breast in women 35 years of age or younger. Ann Surg 169 6 (1969) 839-843
9. Greenlee R.T., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 2000. CA Cancer J Clin 50 1 (2000) 7-33
10. Largent J.A., Ziogas A., and Anton-Culver H. Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer. Breast Cancer Res 7 4 (2005) R541-R554
11. Leslie K.K., and Lange C.A. Breast cancer and pregnancy. Obstet Gynecol Clin N Am 32 (2005) 547-558
12. Partridge A., and Schapira L. Pregnancy and breast cancer: epidemiology, treatment, and safety issues. Oncology (Williston Park) 19 6 (2005) 693-697
13. Fiorica J.V. Special problems: breast cancer and pregnancy. Obstet Gynecol Clin N Am 21 4 (1994) 721-732
14. Osborne C.K., and Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23 8 (2005) 1616-1622
15. Ansquer Y., Legrand A., Bringuier A.F., et al. Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line. Anticancer Res 25 1A (2005) 243-248
16. Dabrosin C. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J Clin Endocrinol Metab 88 6 (2003) 2695-2698
17. Salven P., Lymboussaki A., Heikkilä P., Jääskela-Saari H., Enholm B., Aase K., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 153 (1998) 103-108
18. Engels K., Fox S.B., Whitehouse R.M., Gatter K.C., and Harris A.L. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181 (1997) 207-212
19. Guidi A.J., Fischer L., Harris J.R., and Schnitt S.J. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86 (1994) 614-619
20. Guidi A.J., Schnitt S.J., Fischer L., Tognazzi K., Harris J.R., and Dvorak H.F. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80 (1997) 1945-1953
21. Brown L.F., Guidi A.J., Schnitt S.J., Van De Water L., Iruela-Arispe M.L., Yeo T.K., et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5 (1999) 1041-1056
22. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 1 (2006) 24-40
23. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
24. Miller K.D. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin N Am 18 5 (2004) 1071-1086
25. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. The Oncologist 5 Suppl. 1 (2000) 37-44
26. Bando H., Weich H.A., Brokelmann M., Horiguchi S., Funata N., Ogawa T., et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. British J Cancer 92 (2005) 553-561
27. Evans P.W., Wheeler T., Anthony F.W., and Osmond C. A longitudinal of maternal serum vascular endothelial growth factor in early pregnancy. Human Reprod 13 4 (1998) 1057-1062
28. Abdallah M.A. Human fetal nongonadal tissues contain human chorionic gonadotropin/luteinizing hormone receptors. J Clin Endocrinol Metab 89 2 (2004) 952-956
29. Perkins G.L. Serum tumor markers. Am Fam Physician 68 6 (2003) 1075-1082
30. Lei Z.M., and Rao Ch.V. Endocrinology of the trophoblast tissue. In: Becker K. (Ed). Principles and practice of endocrinology and metabolism. 3rd ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1096-1102 chapater 112
31. Larsen. Williams Textbook of Endocrinology. 10th ed. Copyright © 2003 Elsevier.
32. Braunstein G.D. Evidence favoring human chorionic gonadotropin as the physiological 'rescuer' of the corpus luteum during early pregnancy. Early Pregnancy 2 (1996) 183
33. Wulff C., Dickson S.E., Duncan W.C., and Fraser H.M. Angiogenesis in the human corpus luteum: simulated early pregnancy by HCG treatment is associated with both angiogenesis and vessel stabilization. Human Reprod 16 12 (2001) 2515-2524
34. Funaro A. Functional, structural, and distribution analysis of the chorionic gonadotropin receptor using murine monoclonal antibodies. J Clin Endocrinol Metab 88 11 (2003) 5537-5546
35. Spong C.Y., Ghidini A., Dildy G.A., Loucks C.A., Varner M.W., and Pezzullo J.C. Elevated second-trimester maternal serum hCG: a marker of inadequate angiogenesis. Obstet Gynecol 91 (1998) 605-608
36. Zygmunt M., Herr F., Keller-Schoenwetter S., Kunzi-Rapp K., Münstedt K., Rao C.V., et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrin Metab 87 11 (2002) 5290-5296
37. Zygmunt M. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 110 Suppl. 1 (2003) S10-S18
38. Meduri G., Charnaux N., Loosfelt H., Jolivet A., Spyratos F., Brailly S., et al. Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res 57 (1997) 857-864
39. Lojun S., Bao S., Lei Z.M., and Rao C.V. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. Biol Reprod 57 (1997) 1202-1210
40. Srivastava P., Russo J., Mgbonyebi O.P., and Russo I.H. Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells. Anticancer Res 18 (1998) 4003-4010
41. Tanaka Y., Kuwabara K., Okazaki T., Fujita T., Oizumi I., Kaiho S., et al. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens. Oncology 59 Suppl. 1 (2000) 19-23
42. Rao C.h.V. Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation. J Biol Chem 279 24 (2004) 25503-25510
43. Saigo P.E., and Rosen P.P. Mammary carcinoma with 'choriocarcinomatous' features. Am J Surg Pathol 5 (1981) 773-778
44. Khalbuss W.E. Cytomorphology of rare malignant tumors of the breast. Clin Lab Med 25 4 (2005) 761-775 vii
45. Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L.H., Borg A., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61 16 (2001) 5979-5984
46. Bando H., Toi M., Kitada K., and Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother 57 8 (2003) 333-340
47. Rodway M.R., and Rao C.V. A novel perspective on the role of human chorionic gonadotropin during pregnancy and in gestational trophoblastic disease. Early Pregnancy 1 3 (1995) 176-187
48. Neulen J., Yan Z., Raczek S., Weindel K., Keck C., Weich H.A., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80 6 (1995) 1967-1971
49. Robertson D., Selleck K., Suikkari A.M., Hurley V., Moohan J., and Healy D. Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment. Hum Reprod 10 9 (1995) 2478-2482
50. Krasnow J.S., Berga S.L., Guzick D.S., Zeleznik A.J., and Yeo K.T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 65 3 (1996) 552-555